Raptor Pharmaceutical lifts at market sales agreement to $100 million

Agent Cowen raises funds on a commercially reasonable efforts basis

By Devika Patel

Knoxville, Tenn., July 5 - Raptor Pharmaceutical Corp. increased an at market sales agreement to $100 million from $40 million on July 3, according to an 8-K filed Friday with the Securities and Exchange Commission. The deal priced on April 30.

Agent Cowen and Co., LLC will conduct the sale on a commercially reasonable efforts basis.

Raptor is a Novato, Calif., biotechnology company that bioengineers novel drugs and drug-targeting platforms derived from the human receptor-associated protein and related proteins.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.